GENITOURINARY CANCERS

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> &#8203;

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of&nbsp;medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with&nbsp;metastatic castration-resistant prostate cancer.&nbsp;

Prachi Mishra, PhD, was awarded the first &ldquo;Colonel (Ret.) David G. McLeod Prostate Cancer Translational Research Fellowship&rdquo; at the Uniformed Services University of Health Sciences on December 7. She was presented this award in front of Department of Defense leadership, industry leaders, cancer scientists, military healthcare providers, and other colleagues.

Pembrolizumab (Keytruda) has been approved in Japan for the treatment&nbsp;of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.

Based on results of the Ib/II Study 111, the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib has been granted a breakthrough therapy designation by the FDA for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Arjun Balar, MD,&nbsp;discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.

With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.

Determining the sequence of therapies has yet to be wholly standardized for treating castration-resistant prostate cancer (CRPC), particularly in the case of abiraterone (Zytiga) and enzalutamide (Xtandi).

Therapeutic Management of Nonmetastatic Prostate Cancer

Therapeutic Approach for Nonmetastatic Prostate Cancer

The PD-L1 inhibitor avelumab (Bavencio) has been granted a breakthrough therapy designation by the FDA&nbsp;for use in combination with the VEGF inhibitor axitinib (Inlyta) in treatment-na&iuml;ve patients with advanced renal cell carcinoma.

Based on data from the phase III SPARTAN trial, apalutamide has been granted a priority review by the FDA for the&nbsp;treatment of patients with nonmetastatic castration-resistant prostate cancer, according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

Based on results of the CABOSUN trial, cabozantinib&nbsp;(Cabometyx) has been approved by the FDA for previously untreated patients with advanced renal cell carcinoma.

Based on findings of the phase III CheckMate-214 trial, a&nbsp;supplemental biologics license application for the combination of nivolumab and&nbsp;ipilimumab has been granted a priority review by the FDA&nbsp;as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

According to results of a phase I/II study, men with metastatic castration-resistant prostate cancer who received a second course of radium-223&nbsp;(Xofigo) experienced minimal hematologic toxicity and low radiographic bone progression rates.

Sunitinib (Sutent) has been granted FDA approval for the adjuvant treatment of patients with renal cell carcinoma (RCC) who&nbsp;have received nephrectomy and are high risk for recurrence.